Moderna's stock fell about 7.4% following the release of Phase 3 trial data for its experimental cancer vaccine, intismeran, developed with Merck. The results tempered investor enthusiasm, reflecting that expectations had been very high. Merck's shares remained flat amid the news. This signals a reality check for the vaccine's prospects, though further developments and analyses will be needed to assess its future potential.
Moderna's stock is holding steady with a slight gain of 0.15% at USD 200.40 on Pluang, despite the recent drop noted in the news. Merck's shares are down 0.32% at USD 144.80 as of Oct 26, 2026 21:02 WIB, showing a mild reaction to the vaccine trial results.
Moderna's stock fell 7% after its personalized melanoma vaccine, despite meeting its primary goal in a late-stage trial, showed less impact on distant cancer spread than earlier studies suggested. This has led investors to reassess the commercial pot...
Biotech stocks are rallying strongly in 2026, with the iShares Biotechnology ETF up 24% year-to-date, building on a 28% gain in 2025. Moderna leads with a 587% surge despite a recent dip after positive cancer vaccine data leaked. The sector's growth ...
Moderna and Merck released Phase 3 trial results showing their personalized mRNA cancer vaccine, combined with Keytruda, reduces melanoma recurrence or death risk by 42% compared to Keytruda alone. Specialists see this as a significant breakthrough t...
Moderna's stock dropped 4% following an earlier 18% plunge after the release of positive late-stage results for its personalized melanoma vaccine co-developed with Merck. Although the vaccine showed a reduction in melanoma recurrence risk, the result...
Moderna's shares fell nearly 18% after positive Phase 3 results for its personalized melanoma vaccine with Merck were leaked early, causing market uncertainty despite the promising data. Meanwhile, SpaceX is negotiating with major infrastructure firm...
